Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02575391
Other study ID # 10-107B
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received September 25, 2015
Last updated October 9, 2015
Start date October 2009
Est. completion date September 2012

Study information

Verified date October 2015
Source Providence Health & Services
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study will evaluate whether a Whole Food Intervention reduces the frequency or severity of esophagitis in patients receiving treatment for non-small cell lung cancer.

The Whole Food Intervention consists of yogurt, butter, honey, vanilla, and glutamine with 3 portioning cups, equal to approximately 12 ounces, taken daily before starting radiation therapy.


Description:

The proposal is a one center, open label, randomized pilot study to evaluate the safety, tolerability and compliance of a Whole Food Intervention with Standard of Care for patients with non-small cell lung cancer. The primary objectives are:

1. To determine whether patients will use a Whole Food Intervention 4-6 times daily, and

2. To determine whether the Whole Food Intervention will reduce the incidence of grade 2 or greater esophagitis from 75% historically seen to 25% .

3. To determine whether Whole Food Intervention will reduce the incidence of treatment breaks from >19% to < 10% (see section 9 for comments)

This Whole Food Intervention will be taken by mouth before the start of radiation therapy, with or without chemotherapy and for the entire treatment therapy.

Esophagitis-related pain and reduction of oral intake will be quantified by using validated assessment tools. Weight loss or gain, diarrhea, constipation or no change in bowel function and the use of conventional medication for radiation-induced esophagitis will be recorded. Chart review and patient questionnaires will be used to establish whether a treatment break or dose reduction for radiation of chemotherapy was required due to radiation esophagitis-related symptoms. Complete Chemistry Profile and Complete Blood Count will be extracted from the patients' medical oncologist's or radiation oncologist's records. The patient will continue to use standard esophagitis therapies if desired as prescribed by the treating oncology physician.

The Whole Food Intervention consists of yogurt, butter, honey, vanilla, and glutamine with 3 portioning cups, equal to approximately 12 ounces, taken daily before starting radiation therapy. A questionnaire will be used to record symptoms and doses taken. The patient will continue to use standard esophagitis therapies as prescribed by the treating oncology physician.


Recruitment information / eligibility

Status Terminated
Enrollment 7
Est. completion date September 2012
Est. primary completion date September 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histopathologically confirmed diagnosis of thoracic carcinoma

- Scheduled to undergo continuous daily course of radiation therapy with or without chemotherapy

- No other serious concurrent medical illness as determined by the Principle Investigator

- Absolute neutrophil count = 500/mm3

- Platelet count = 50,000/mm3

- No history of insulin-dependent diabetes mellitus

- No prior hypersensitivity reaction to compound components

Exclusion Criteria:

- Dislike of the available forms of the WFI

- Allergy or food intolerance relevant to the ingredients

- Lack of access to refrigerated storage for the WFI

- Inability or unwillingness to participate twice a week

- Inability to swallow

- Undergoing treatment for HIV with HIV medications

- Ongoing alcohol and/or drug abuse

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Whole Food Intervention
A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.

Locations

Country Name City State
United States Integrative Medicine Program, Providence St. Vincent Medical Center Portland Oregon
United States The Oregon Clinic, Providence Portland Cancer Center Portland Oregon

Sponsors (1)

Lead Sponsor Collaborator
Providence Health & Services

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of Tolerability Estimated portion consumption on a daily basis was obtained to determine if the WFI could be tolerated by participants. Eight (8) weeks No
Secondary Esophagitis Grading Esophagitis grade was calculated using established criteria. Eight (8) weeks No
Secondary Treatment Break Measurement To determine whether Whole Food Intervention will reduce the incidence of treatment breaks from =19% to =10%. Eight (8) weeks No
See also
  Status Clinical Trial Phase
Completed NCT00284908 - Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers Phase 1
Completed NCT00272818 - Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
Recruiting NCT05326113 - The Effect of Physiotherapy on Post POEM Reflux N/A
Recruiting NCT01696734 - Domperidone in Treating Patients With Gastrointestinal Disorders Phase 3
Completed NCT00123630 - A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Phase 2
Completed NCT00256529 - Prospective Analysis of Eosinophilic Esophagitis in Patients Presenting With Dysphagia N/A
Completed NCT00081315 - Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer Phase 2
Completed NCT00471094 - Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis Phase 2
Completed NCT00579410 - Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule N/A
Recruiting NCT05109819 - Esophagus-sparing Radiotherapy for Metastatic Spinal Cord Compression. N/A
Withdrawn NCT01824199 - CYP2C19 Genotype Predictor of Gastric Acid Suppression Early Phase 1
Completed NCT01556919 - Esophageal Monitoring Device for Assessing Mucosal Impedance
Active, not recruiting NCT03835663 - The Bacterial Composition of the Stomach in Reflux Disease
Completed NCT00195208 - Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis Phase 3
Completed NCT00175045 - Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis Phase 2
Completed NCT05129670 - Clinical Investigation to Assess the Acid Neutralisation Activity of a Calcite Chewing Gum N/A
Recruiting NCT05004155 - Twenty Four Hour Ambulatory pH & Impedance Testing: Normative Data for Indian Population
Completed NCT03228147 - Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment N/A
Completed NCT00133770 - Intravenous (IV) Pantoprazole in Erosive Esophagitis Phase 4
Completed NCT01322633 - Risk of Cancer Among Pantoprazole Users N/A